Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15.08. | VISEN PHARMA-B (02561): DATE OF BOARD MEETING | - | HKEx | ||
27.06. | VISEN PHARMA-B (02561): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
VISEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
27.06. | VISEN PHARMA-B (02561): (1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 27 JUNE 2025; (2) RETIREMENT OF NON-EXECUTIVE DIRECTORS; (3) CHANGE OF ... | - | HKEx | ||
12.06. | VISEN PHARMA-B (02561): SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING | 2 | HKEx | ||
12.06. | VISEN PHARMA-B (02561): SECOND FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 27 JUNE 2025 AT 3:00 P.M. | 1 | HKEx | ||
12.06. | VISEN PHARMA-B (02561): (1) CONTINUING CONNECTED TRANSACTION IN RELATION TO THE COMMERCIAL SUPPLY FRAMEWORK AGREEMENT; (2) PROPOSED GRANT OF AWARD SHARES; ... | - | HKEx | ||
12.06. | VISEN PHARMA-B (02561): GRANT OF AWARD SHARES | 3 | HKEx | ||
12.06. | VISEN PHARMA-B (02561): CONTINUING CONNECTED TRANSACTION COMMERCIAL SUPPLY FRAMEWORK AGREEMENT | - | HKEx | ||
30.04. | VISEN PHARMA-B (02561): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
30.04. | VISEN PHARMA-B (02561): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 27 JUNE 2025 AT 3:00 P.M. | - | HKEx | ||
30.04. | VISEN PHARMA-B (02561): (1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES ... | - | HKEx | ||
30.04. | VISEN PHARMA-B (02561): 2024 ANNUAL REPORT | - | HKEx | ||
25.04. | VISEN PHARMA-B (02561): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
25.04. | VISEN PHARMA-B (02561): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
17.04. | VISEN PHARMA-B (02561): STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF THE OVER-ALLOTMENT OPTION | 3 | HKEx | ||
27.03. | VISEN PHARMA-B (02561): FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024 | - | HKEx | ||
24.03. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 24.03.2025 | 562 | Xetra Newsboard | The following instruments on XETRA do have their first trading 24.03.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 24.03.2025
Aktien
1 KYG93Y5D1039 VISEN Pharmaceuticals
2... ► Artikel lesen | |
20.03. | VISEN PHARMA-B (02561): ANNOUNCEMENT OF ALLOTMENT RESULTS | 2 | HKEx | ||
20.03. | VISEN PHARMA-B (02561): CLARIFICATION ANNOUNCEMENT IN RELATION TO PRINCIPAL PLACE OF BUSINESS IN HONG KONG | 1 | HKEx | ||
19.03. | VISEN PHARMA-B (02561): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 42,125 | +0,12 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen nach einer Investorenveranstaltung auf "Buy" mit einem Kursziel von 52 US-Dollar belassen. Das Interesse der Teilnehmer... ► Artikel lesen | |
EVOTEC | 5,972 | -2,03 % | Puma, Evotec, Globex Mining Aktie: INSIDERALARM und KAUFEMPFEHLUNG! | Insideralarm bei Puma. Wird damit das Comeback der Aktie eingeleitet? Neben dem Kauf von Aktien durch einen Vorstand äußern sich auch Analysten optimistisch. Der Turnaround des Sportartikelherstellers... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES | 47,900 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline | ||
LENZ THERAPEUTICS | 38,640 | 0,00 % | H.C. Wainwright hebt Kursziel für LENZ Therapeutics auf 56 US-Dollar an | ||
BIONTECH | 90,10 | +0,11 % | BioNTech Aktie: Entscheidung an dieser Kursmarke! Steht die große Wende bevor? | © Foto: Bild von felixioncool auf PixabayBioNTech kennt jeder als Corona-Impfstoff-Pionier. Doch längst arbeitet das Mainzer Unternehmen fieberhaft an der nächsten Revolution: Krebs soll mit derselben... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 26,990 | 0,00 % | Positive Studiendaten von Akeso beflügeln Aktie von Summit Therapeutics | ||
AVIDITY BIOSCIENCES | 46,990 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
INVIVYD | 1,035 | 0,00 % | Invivyd rallies amid interest in COVID therapy | ||
RECURSION PHARMACEUTICALS | 4,835 | 0,00 % | Why Recursion Pharmaceuticals Stock Caught a Cold This Week | ||
VALNEVA | 3,770 | -0,53 % | Valneva-Aktie on fire: Das ist jetzt noch drin | Völlig außer Rand und Band präsentiert sich derzeit die Aktie des französischen Impfstoffherstellers Valneva. Sie hat ihren Wert in den letzten sechs Wochen in etwa verdoppelt und ist zuletzt auf ein... ► Artikel lesen | |
PHATHOM PHARMACEUTICALS | 12,565 | 0,00 % | Phathom Pharmaceuticals clarifies no reduction in Frazier ownership | ||
ALUMIS | 4,780 | -2,45 % | Alumis Inc.: Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus | -Topline Readout Expected in Q3 2026- SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted... ► Artikel lesen | |
DYNE THERAPEUTICS | 13,370 | 0,00 % | Dyne Therapeutics stock rises after Raymond James upgrade to Strong Buy | ||
MODERNA | 21,200 | -0,28 % | Moderna, Inc.: Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1 | All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna announced today that Health Canada has authorized... ► Artikel lesen | |
THARIMMUNE | 6,250 | 0,00 % | Tharimmune Inc.: Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments | RED BANK, NJ / ACCESS Newswire / August 20, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic... ► Artikel lesen |